Crinetics Pharmaceuticals, Inc. (CRNX)
NEUTRALファンダメンタル
42
株価
$84.83
時価総額
$9.00B
パート1 · 企業の価値
概要
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$42M
直近12か月（2026/6/30まで）
純利益
$-502M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$-384M
自己資本合計
$992M
負債合計
$134M
流動比率
15.57
利払い倍率
-
負債/EBITDA
-
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$85.50
現在株価
$84.83
安全マージン
+0.8%
適正価値レンジ
$81.22 - $89.78
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-46.9%
P/B レシオ
7.54
P/FCF
-
粗利益率
86.0%
ROIC
-34.9%
収益性レーダー
Value Creation (Economic Moat)
ROIC
-34.9%
WACC
8.0%
ROIC − WACC
-42.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
ファンダメンタル分析基準
合格（8）
- EPS shows upward trend
- Price CAGR 13.86%
- Gross Margin 86.0%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Revenue Growth 5Y 156.0%
- Net Margin Trend -1189.9% vs -26568.5%
不合格（11）
- ROIC -34.9%
- P/B Ratio 7.54
- Operating Margin -1302.5%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -44.2%
- Analyst Consensus 33% Buy
- Earnings Surprise avg 2.5%
- Share Dilution 16.2%
- Piotroski F-Score 2/9
データなし（8）
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質：会計処理を調査してください
株式希薄化
新株を発行しており、所有権を希薄化している
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. R. Scott Struthers Ph.D. | Founder, President, CEO & Director | 63 |
| Dr. Stephen F. Betz Ph.D. | Co-Founder & Chief Scientific Officer | 59 |
| Mr. Tobin C. Schilke | Chief Financial Officer | 50 |
| Mr. Kea Lingo | Chief Information Officer | - |
| Ms. Gayathri Diwakar | Head of Investor Relations | - |
| Ms. Garlan Adams J.D. | Chief Legal Officer & Corporate Secretary | - |
| Natalie Badillo | Head of Corporate Communications | - |
| Ms. Adriana C. Cabre M.B.A. | Chief Human Resources Officer | - |
| Dr. Alan S. Krasner M.D. | Chief Endocrinologist | 62 |
| Mr. Kevin Capps | Head of Intellectual Property | - |
監査リスク
3
取締役会リスク
6
報酬リスク
9
株主権利リスク
8
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for CRNX, sourced from Markets Gazette.
- 2/27/2026NEUTRALCrinetics (CRNX) Q4 2025 Earnings Call Transcript
The financial community is keenly awaiting the transcript of Crinetics Pharmaceuticals' Q4 2025 earnings call, scheduled for February 27, 2026. While the specific content remains unavailable, such events are pivotal for investors, providing crucial details on revenue, earnings per share, and future outlook. Analyzing this data is essential for assessing performance and growth strategies, directly influencing trading decisions for CRNX stock. The current lack of immediate information prevents an in-depth analysis, leaving market participants in anticipation of further disclosures that could move the stock.
via Markets Gazette